
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is uniquely positioned to address the unmet medical need of obesity and cardiometabolic diseases through its innovative AI-guided technology and promising pipeline of novel antibody therapeutics. Its lead asset, IBIO-600, has shown potential to treat these conditions in pre-clinical studies and is expected to enter the clinic in the first half of 2027. While competition and regulatory risks are present, positive clinical outcomes and potential market demand for these therapies could contribute to the Company's future success.
Bears say
iBio is also facing increasing debt and negative operating cash flow, indicating a need for additional funding. Overall, the company's lack of revenue and high-risk development stage make it an unfavorable investment with dim future prospects.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares